Cardiovascular Systems Sponsoring Lunch Symposium on Arterial Calcium at 2013 VIVA Conference

Cardiovascular Systems Sponsoring Lunch Symposium on Arterial Calcium at 2013 VIVA Conference

Company Also Featuring Hands-on Cadaver Mobile Lab Training Session

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI) (NAS: CSII) , is sponsoring a lunch symposium highlighting the challenges and treatment options for Peripheral Arterial Disease complicated by calcium at the 2013 Vascular Interventional Advances (VIVA) conference in Las Vegas, Oct. 8-11, 2013. In order to enhance this learning opportunity, CSI will also host a hands-on training session in its mobile lab using cadavers to train attendees on pedal access and the use of orbital atherectomy.


CSI-Sponsored Lunch Symposium: Oct. 10

WHAT: Industry leaders will share their expertise on issues related to the treatment of arterial calcium during a lunch symposium sponsored by CSI. The symposium, titled "Arterial Calcium: Challenges and Treatments," will cover the implications of calcium in device selection, treatment options and outcomes with orbital atherectomy. It will address treatment techniques in complex cases as well as the limitations and considerations of emerging drug-coated and bioresorbable platforms. The symposium will be moderated by John Rundback, MD, Holy Name Medical Center, Teaneck, N.J.

     

TOPICS:

--

Prevalence of Calcium and Implications for Infrapopliteal Device Selection - Lawrence Garcia, MD, St. Elizabeth's Medical Center, Brighton, Mass.

--

Clinical Outcomes of OAS Treatment Options for Infrapopliteal Patients - John Rundback, MD, Holy Name Medical Center, Teaneck, N.J.

--

Simple Techniques for Complex Cases - Arthur Lee, MD, Cardiac & Vascular Institute, Lake City Medical Center, North Florida Regional Medical Center, Gainesville, Fla.

--

Limitations of Current Drug Eluting and Bioresorbable Technologies - Biological Considerations for Future Device Selection - Thomas Zeller, MD, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany

--

Panel Discussion

 

WHEN:

Thursday, Oct. 10, 12:00 - 1:15 p.m.
 

WHERE:

Lafite 7, Wynn Las Vegas
3131 Las Vegas Blvd. S.
Las Vegas, NV 89109
 

Mobile Training Lab: Oct. 10

WHAT: CSI will host a cutting-edge, hands-on cadaver lab at VIVA, featuring ultrasound guided tibial and pedal access followed by orbital atherectomy treatment.

     

WHEN:

Thursday, Oct. 10, 5:30 p.m.
 

WHERE:

Mouton 2, Wynn Las Vegas
3131 Las Vegas Blvd. S.
Las Vegas, NV 89109
 

CSI Booth at VIVA: Oct. 8-10

Visit CSI at booth #406, 7 a.m. - 4:15 p.m., Tuesday, Oct. 8; Wednesday, Oct. 9; and Thursday, Oct. 10.

About Peripheral Arterial Disease (PAD)
PAD is a life-threatening condition where a fatty material called plaque builds up on the inside walls of the blood vessels that carry blood from the heart to legs and arms. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or personal history of heart disease, heart attack or stroke. PAD affects an estimated 8-12 million people in the United States. The disease prevalence increases with age and 12-20 percent of Americans age 65 and older suffer from PAD symptoms. As the U.S. population ages, the prevalence range could reach 16 million in those age 65 and older and 19 million overall by 2050.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, nearly 110,000 of CSI's devices have been sold to leading institutions across the United States. CSI has also completed its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.

For more information, visit the company's website at www.csi360.com.



For Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
Sarah Wozniak, 651-259-1636
swozniak@csi360.com
or
PadillaCRT:
Matt Sullivan, 612-455-1709
msullivan@padillacrt.com
or
Dave Folkens, 612-455-1741
dfolkens@padillacrt.com

KEYWORDS:   United States  North America  Minnesota  Nevada

INDUSTRY KEYWORDS:

The article Cardiovascular Systems Sponsoring Lunch Symposium on Arterial Calcium at 2013 VIVA Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.